Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DCC-2618 · 1 trial · 1 indication
Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).
| Arm | Type | Description |
|---|---|---|
| DCC-2618 | EXPERIMENTAL | DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle. |
| Name | Type | Description |
|---|---|---|
| DCC-2618 | DRUG | Oral kinase inhibitor |
Inclusion Criteria: * Male or female patients ≥18 years of age. * Patients with advanced gastrointestinal stromal tumors. * Subjects who have progressed or documented intolerance after previous treatments. * Sign informed consent, understand the Protocol and could follow the Protocol. * The subject...
DCC-2618 is a small molecule being studied for the treatment of advanced gastrointestinal stromal tumors (GIST). It is an investigational drug currently in clinical development and has not been approved by regulatory authorities.
DCC-2618 is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting clinical research on this drug for gastrointestinal stromal tumors.
DCC-2618 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for safety and efficacy.
DCC-2618 has been studied in one completed Phase 2 clinical trial with the identifier NCT04282980. This trial enrolled 39 participants with advanced gastrointestinal stromal tumors and was conducted in China.
Yes, DCC-2618 is also known as ripretinib. The clinical trial NCT04282980 refers to the drug as DCC-2618 (Ripretinib), confirming that these names refer to the same investigational compound.